Search hospitals > Missouri > Kansas City
Saint Luke's Cancer Institute at Saint Luke's Hospital
Claim this profileKansas City, Missouri 64111
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Leukemia
Conducts research for Cancer
Conducts research for Lymphoma
115 reported clinical trials
3 medical researchers
Summary
Saint Luke's Cancer Institute at Saint Luke's Hospital is a medical facility located in Kansas City, Missouri. This center is recognized for care of Breast Cancer, Lung Cancer, Leukemia, Cancer, Lymphoma and other specialties. Saint Luke's Cancer Institute at Saint Luke's Hospital is involved with conducting 115 clinical trials across 179 conditions. There are 3 research doctors associated with this hospital, such as Timothy Pluard, Janakiraman Subramanian, and Shahzad Raza, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
ER positive
Stage III
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Timothy PluardSaint Luke's Cancer Institute LLC1 year of reported clinical research
Studies Breast Cancer
Studies Tumors
13 reported clinical trials
23 drugs studied
Janakiraman SubramanianSaint Luke's Hospital of Kansas City5 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
10 reported clinical trials
20 drugs studied
Shahzad Raza, MDSaint Luke's Hospital of Kansas City9 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
3 reported clinical trials
6 drugs studied
Clinical Trials running at Saint Luke's Cancer Institute at Saint Luke's Hospital
Breast Cancer
Solid Tumors
Glioblastoma
Gynecologic Cancers
Head and Neck Squamous Cell Carcinoma
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Samuraciclib + Fulvestrant
for Breast Cancer
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.
Recruiting1 award Phase 28 criteria
PF-07220060 + PF-07104091
for Breast Cancer
This trial tests two new oral medicines, PF-07220060 and PF-07104091, in people with different types of breast cancer. It aims to find the safest and most effective dose by gradually increasing the amount given to participants. The study will last several years, during which participants will be monitored for safety and treatment effects.
Recruiting1 award Phase 1 & 215 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Saint Luke's Cancer Institute at Saint Luke's Hospital?
Saint Luke's Cancer Institute at Saint Luke's Hospital is a medical facility located in Kansas City, Missouri. This center is recognized for care of Breast Cancer, Lung Cancer, Leukemia, Cancer, Lymphoma and other specialties. Saint Luke's Cancer Institute at Saint Luke's Hospital is involved with conducting 115 clinical trials across 179 conditions. There are 3 research doctors associated with this hospital, such as Timothy Pluard, Janakiraman Subramanian, and Shahzad Raza, MD.